Aktienanalyse zu Conmed Corp (CNMD)CNMDConmed Corp

CONMED Corporation is a medical technology company which provides devices and equipment for surgical procedures. Its products are used by surgeons and other healthcare professionals in a variety of specialties, including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology. Its product line consists of orthopedic surgery and general surgery. Orthopedic surgery consists of sports medicine instrumentation and lower extremities instrumentation and implants, small bone, large bone and specialty-powered surgical instruments as well as imaging systems for use in minimally invasive surgical procedures and service fees related to the promotion and marketing of sports medicine allograft tissue. General surgery consists of a complete line of endo-mechanical instrumentation for minimally invasive laparoscopic and gastrointestinal procedures, smoke evacuation devices, a line of cardiac monitoring products as well as electrosurgical generators and related instruments. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).

Conmed Corp (CNMD) is currently trading at $44.42, which is significantly below the average analyst target price of $111.62. However, the stock has a low RSI of 37.506, indicating it may be oversold. The forward P/E ratio is 27.17, suggesting that the stock is relatively expensive compared to its earnings potential. The recent 5-day change is -4.10%, indicating a downward trend, while the YTD change is +9.62%, showing overall positive performance this year. The main risk is the recent downgrade by BofA to Underperform with a target of $40, which could indicate further downside potential. Overall, while there are positive catalysts such as earnings beats and revenue growth, the current technical indicators and analyst sentiment suggest holding off on buying until more favorable conditions arise.

6 analysts cover CNMD: 2 rate it Buy, 4 Hold and 0 Sell. The average price target is 50.00.